Dystrophin Immunity in Duchenne's Muscular Dystrophy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
We report on delivery of a functional dystrophin transgene to skeletal muscle in six patients with Duchenne's muscular dystrophy. Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle. Circulating dystrophin-specific T cells were unexpectedly detected in two patients before vector treatment. Revertant dystrophin fibers, which expressed functional, truncated dystrophin from the deleted endogenous gene after spontaneous in-frame splicing, contained epitopes targeted by the autoreactive T cells. The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for this disease. (Funded by the Muscular Dystrophy Association and others; ClinicalTrials.gov number, NCT00428935.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the first mini-dystrophin clinical trial (NCT00428935), completed in 2010, most parsimoniously failed due to immune responses developed against the transgene, which was delivered in the biceps muscle using the AAV2.5 vector [122].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [122]
In the citing paper
“To date, transgene immune responses in AAV gene therapy have been mostly reported in muscle-directed clinical trials [94, 115–119].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Similarly, capsid-specific T-cell responses were limited or not observed in DMD clinical trials [94, 95].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [94]
In the citing paper
“Interestingly, pre-existing cellular immunity to dystrophin may occur in some patients with Duchene’s muscular dystrophy, a disease characterized by muscle regeneration and some level inflammation (55).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
In the citing paper
“In clinical trials, CD8+ T cell responses have been observed against dystrophin and α1-antitrypsin in treatment of Duchenne’s muscular dystrophy and α1-antitrypsin (AAT) deficiency, respectively (55, 56).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [55]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citation
Research works printed but not linked: 1
- Klein CJ, 1992, Am J Hum Genet, 50, 950
Cited by
Items 201–300 of 680
Porcine Models of Muscular Dystrophy
Selsby, J. T., Ross, J. W., Nonneman, D., & Hollinger, K. (2015) · ILAR Journal · doi:10.1093/ilar/ilv015 · Cited by 61
Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion
Mendell, J. R., Chicoine, L. G., Al-Zaidy, S. A., Sahenk, Z., Lehman, K. J., Lowes, L. P., Miller, N. F., Alfano, L. N., Galliers, B., Lewis, S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.006 · Cited by 54
Self-citationAccurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry
Marathi, K. J. B. R., & Fiorillo, A. A. (2013) · Journal of Bioanalysis & Biomedicine · doi:10.4172/1948-593x.s7-001 · Cited by 51
“These include exon skipping with antisense oligonucleotide [6,10], stop codon read-through with Ataluren (PTC124) drug [7], gene therapy [26] and stem cell therapy [27].”
BackgroundFollistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy
Al-Zaidy, S. A., Sahenk, Z., Rodino-Klapac, L. R., Kaspar, B., & Mendell, J. R. (2015) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-150083 · Cited by 47
Self-citationRecent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia
Ajufo, E., & Cuchel, M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0579-0 · Cited by 51
Muhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., Nixon, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674242 · Cited by 50
“However, targeting muscle tissues can result in immune reactions, and anti-transgene responses have been mostly documented in gene therapy trials involving intramuscular delivery of rAAV vectors (28, 29).”
BackgroundSelf-citationMembrane-stabilizing copolymers confer marked protection to dystrophic skeletal muscle in vivo
Houang, E. M., Haman, K. J., Filareto, A., Perlingeiro, R. C. R., Bates, F. S., Lowe, D. A., & Metzger, J. M. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.42 · Cited by 51
SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice
Shin, J., Bostick, B., Yue, Y., Hajjar, R. J., & Duan, D. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-132 · Cited by 54
The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination
Bentley, E. M., Mather, S. T., & Temperton, N. J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.04.071 · Cited by 57
“A Phase I clinical trial using a poorly designed constitutively expressing mini-dystrophin cassette packaged in an AAV2.5 pseudotype, characterised by high sero-prevalence in the human population, resulted in dystrophin immunity/vaccine type outcome [37] .”
BackgroundCoaxing stem cells for skeletal muscle repair
McCullagh, K. J. A., & Perlingeiro, R. C. R. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.007 · Cited by 54
“However, unexpected immune responses to dystrophin delivery observed during clinical trials is an added challenge that is under address now [1,9].”
BackgroundInfluentialEvolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
D'Ambrosio, E. S., & Mendell, J. R. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01423-y · Cited by 49
“It had been previously established that expression of the gene into a deleted domain of the patient’s mutation was immunogenic [69].”
BackgroundSelf-citationThe curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Genetic Therapeutic Approaches for Duchenne Muscular Dystrophy
Foster, H., Popplewell, L. J., & Dickson, G. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.099 · Cited by 52
“…generation of both cytotoxic and humoral immune responses to the capsid of various rAAVs (Manno et al ., 2006; Mingozzi and High, 2007; Mingozzi et al ., 2007b; Mendell et al ., 2010a; Bowles et al ., 2012), the development of which appears to be dose dependent in humans (Mingozzi et al ., 2009).”
Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles
Peccate, C., Mollard, A., Hir, M. L., Julien, L., McClorey, G., Jarmin, S., Heron, A. L., Dickson, G., Benkhelifa‐Ziyyat, S., Piétri‐Rouxel, F., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw201 · Cited by 49
Spampanato, C., De Leonibus, E., Dama, P., Gargiulo, A., Fraldi, A., Sorrentino, N. C., Russo, F., Nusco, E., Auricchio, A., Surace, E. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.299 · Cited by 44
Scripture-Adams, D. D., Chesmore, K. N., Barthélémy, F., Wang, R. T., Nieves‐Rodriguez, S., Wang, D. W., Mokhonova, E. I., Douine, E. D., Wan, J., Little, I., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03938-0 · Cited by 52
Ligand targeting and peptide functionalized polymers as non-viral carriers for gene therapy
Muhammad, K., Zhao, J., Ullah, I., Guo, J., Ren, X., & Feng, Y. (2019) · Biomaterials Science · doi:10.1039/c9bm01112a · Cited by 47
Gernoux, G., Gruntman, A. M., Blackwood, M., Zieger, M., Flotte, T. R., & Mueller, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.004 · Cited by 44
Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
Mbakam, C. H., Lamothe, G., & Tremblay, J. P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.859930 · Cited by 49
“(124) raised attention a decade ago about the consideration of cellular immunity against self and non-self dystrophin epitopes for the mini dystrophin gene transfer.”
BackgroundAAV-based shRNA silencing of NF-κB ameliorates muscle pathologies in mdx mice
Yang, Q., Tang, Y. M., Imbrogno, K., Lu, A., Proto, J. D., Chen, A., Guo, F., Fu, F., Huard, J., & Wang, B. (2012) · Gene Therapy · doi:10.1038/gt.2011.207 · Cited by 55
Yuan, Z., Qiao, C., Hu, P., Li, J., & Xiao, X. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.241 · Cited by 42
“…using AAV vectors to treat genetic diseases such as hemophilia (Margaritis and High, 2010), muscular dystrophy (Wang et al., 2000; Chamberlain, 2002; Mendell et al., 2009, 2010a,b), Leber’s congenital amaurosis (Maguire et al., 2008, 2009), and alpha-1 antitrypsin deficiency (Brantly et al., 2009).”
MethodSelf-citationGene Therapy for Muscular Dystrophy: Moving the Field Forward
Al-Zaidy, S. A., Rodino‐Klapac, L. R., & Mendell, J. R. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.08.002 · Cited by 47
“In a first clinical gene therapy trial of its kind in DMD, six boys were enrolled in a double blind randomized controlled dose escalation study evaluating safety and efficacy of dystrophin gene transfer [37].”
BackgroundSelf-citationDuchenne muscular dystrophy: clinical trials and emerging tribulations
Shieh, P. B. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000243 · Cited by 45
Guilbaud, M., Devaux, M., Couzinié, C., Le Duff, J., Toromanoff, A., Vandamme, C., Jaulin, N., Gernoux, G., Larcher, T., Moullier, P., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.234 · Cited by 45
“In clinical trials, the limited number of available data seems to indicate that the impact of anti-transgene immune responses on rAAV-mediated gene transfer efficiency is not as predictive as animal models led us to expect.(13,18) Indeed, their occurrence seems not to be systematically correlated to the loss of transg…”
BackgroundPeay, H. L., Fischer, R. A., Tzeng, J., Hesterlee, S. E., Morris, C. A., Martin, A. S., Rensch, C., Smith, E. C., Ricotti, V., Beaverson, K. L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213649 · Cited by 45
Arjomandnejad, M., Sylvia, K., Blackwood, M., Nixon, T., Tang, Q., Muhuri, M., Gruntman, A. M., Gao, G., Flotte, T. R., & Keeler, A. M. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.010 · Cited by 44
Lorain, S., Peccate, C., Hir, M. L., Griffith, G., Philippi, S., Précigout, G., Mamchaoui, K., Jollet, A., Voït, T., & García, L. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt621 · Cited by 45
“However, one must keep in mind that preexisting immunity against dystrophin has been noticed in some DMD patients, so immune response against full-length dystrophin might preclude dystrophin rescue strategies (51).”
BackgroundTargeted gene therapies: tools, applications, optimization
Humbert, O., Davis, L., & Maizels, N. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.658112 · Cited by 50
“…as evident in experiments that attempted to treat muscular dystrophy with a minigene version of the very large (79 exon) dystrophin gene (Mendell et al., 2010; Moore & Flotte, 2010). rAAV vectors can also be used to introduce defined sequence changes at homologous chromosomal loci, in…”
BackgroundTherapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy
Farini, A., Sitzia, C., Cassani, B., Cassinelli, L., Rigoni, R., Colleoni, F., Fusco, N., Gatti, S., Bella, P., Villa, C., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.162 · Cited by 48
Regulatory and Exhausted T Cell Responses to AAV Capsid
Gernoux, G., Wilson, J. M., & Mueller, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.022 · Cited by 44
“56 Thus, this immunosuppressive treatment does not seem to prevent the reactivation of specific T cells to the transgene.”
Current and Emerging Therapies for Duchenne Muscular Dystrophy
Crone, M., & Mah, J. K. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0513-6 · Cited by 45
Schinkel, S., Bauer, R., Bekeredjian, R., Stucka, R., Rutschow, D., Lochmüller, H., Kleinschmidt, J. A., Katus, H. A., & Müller, O. J. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.017 · Cited by 45
“Whereas clinical gene transfer experiments using l Dys constructs are underway for skeletal muscle in boys with DMD (Mendell et al. , 2010), gene therapy for heart failure in dystrophin deficiency has barely been evolved.”
Heller, K. N., Montgomery, C. L., Janssen, P. M. L., Clark, K. R., Mendell, J. R., & Rodino‐Klapac, L. R. (2013) · Molecular Therapy · doi:10.1038/mt.2012.281 · Cited by 48
Self-citationTranslating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
“Patients with large frameshift deletions also risk T cell-directed destruction against the new epitopes.(117,118) The lack of long-term effects could also be due to constant muscle degeneration and regeneration, diluting the expression of the nonintegrated transgene with time.”
Gene therapy for Duchenne muscular dystrophy
Verhaart, I. E. C., & Aartsma-Rus, A. M. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328357b0be · Cited by 53
TRPCs: Influential Mediators in Skeletal Muscle
Choi, J. H., Jeong, S. Y., Oh, M. R., Allen, P. D., & Lee, E. H. (2020) · Cells · doi:10.3390/cells9040850 · Cited by 44
Gougeon, M.-L., Poirier-Beaudouin, B., Ausseil, J., Zérah, M., Artaud, C., Heard, J.-M., Deiva, K., & Tardieu, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655478 · Cited by 38
“Evidence of T cell-mediated anti-transgene cytotoxic T cell responses was documented in a phase 1/2 trial of intramuscular AAV-mediated gene transfer in Duchenne muscular dystrophy patients, where poor expression of dystrophin was associated with the detection of transgene-specific polyfunctional CD8 T cells (45).”
BackgroundLaing, N. G., Davis, M. R., Bayley, K., Fletcher, S., & Wilton, S. D. (2011) · Europe PMC (PubMed Central) · Cited by 63
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
“A major barrier to muscle gene transfer is the need to deliver the replacement gene body wide, necessitating multiple injections into various sites throughout the body, thereby increasing the potential for inflammatory immune responses (71, 72).”
BackgroundThe AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD
Wang, J.-Z., Wu, P., Shi, Z.-M., Xu, Y.-L., & Liu, Z.-J. (2017) · Brain and Development · doi:10.1016/j.braindev.2017.03.024 · Cited by 41
“detected dystrophin-specific T cell response after delivering exogenous dystrophin transgene into skeletal muscle of six DMD patients [70].”
Translating musculoskeletal bioengineering into tissue regeneration therapies
Khodabukus, A., Guyer, T., Moore, A. C., Stevens, M. M., Guldberg, R. E., & Bursac, N. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9074 · Cited by 44
TNNT1 nemaline myopathy: natural history and therapeutic frontier
Fox, M. D., Carson, V. J., Feng, H., Lawlor, M. W., Gray, J. T., Brigatti, K. W., Jin, J. P., & Strauss, K. A. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy233 · Cited by 42
Okada, T., & Takeda, S. (2013) · Pharmaceuticals · doi:10.3390/ph6070813 · Cited by 45
“Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle [98].”
BackgroundMitrani‐Rosenbaum, S., Yakovlev, L., Becker‐Cohen, M., Telem, M., Elbaz, M., Yanay, N., Yotvat, H., Shlomo, U. B., Harazi, A., Fellig, Y., et al. (2012) · Neuromuscular Disorders · doi:10.1016/j.nmd.2012.03.013 · Cited by 43
“It should be noted that immune response to the normal transgene GNE itself is of much less concern in the specific case of GNE myopathy, compared to the situation in Duchenne muscular dystrophy [29], since in GNE myopathy patients the mutated GNE protein is expressed at normal levels [30].”
ResultPotter, R. A., Moeller, I. H., Khan, S. Z., Haegel, H., Hollenstein, A., Steiner, G., Wandel, C., Murphy, A. P., Asher, D. R., Palatinsky, E. A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84077-w · Cited by 41
Self-citationGene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Internal deletion compromises the stability of dystrophin
Henderson, D. M., Belanto, J. J., Li, B., Heun‐Johnson, H., & Ervasti, J. M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr199 · Cited by 38
Present and Future of Adeno Associated Virus Based Gene Therapy Approaches
Ortolano, S., Spuch, C., & Navarro, C. (2012) · Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · doi:10.2174/187221412799015245 · Cited by 35
Nelke, C., Schmid, S., Kleefeld, F., Schroeter, C. B., Goebel, H., Hoffmann, S., Preuße, C., Kölbel, H., Meuth, S. G., Ruck, T., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02669-8 · Cited by 38
“I detected on myofibers [47].”
Gee, P., Xu, H., & Hotta, A. (2017) · Stem Cells International · doi:10.1155/2017/8765154 · Cited by 39
“Unfortunately, viralmediated delivery of microdystrophin into patients failed to establish sustained protein expression, possibly due to an immune response [24].”
BackgroundMethodOnasemnogene abeparvovec for the treatment of spinal muscular atrophy
McMillan, H. J., Proud, C. M., Farrar, M. A., Alexander, I. E., Muntoni, F., & Servais, L. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2066471 · Cited by 39
“therapies should consider the potential for target cell destruction by T cells directed against non-self epitopes encoded by therapeutic transgenes [94].”
BackgroundGene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors
Seto, J. T., Ramos, J. N., Muir, L. A., Chamberlain, J. S., & Odom, G. L. (2012) · Current Gene Therapy · doi:10.2174/156652312800840603 · Cited by 43
Wu, C.-J., Chen, L., Huang, W., Chuang, C.-L., & Kuo, M. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.039 · Cited by 47
“Although AAV2 has been one of the most commonly used serotypes of AAV (Bainbridge et al. , 2008; Marks et al. , 2008; McPhee et al. , 2006; Mendell et al. , 2010; Worgall et al. , 2008), recombinant AAVs composed of rep gene from AAV2 and cap gene from different serotypes can be used to enhance…”
The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy
Bengtsson, N. E., Tasfaout, H., & Chamberlain, J. S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.065 · Cited by 41
“89,90 93 Six different biotech groups have entered the AAV-μ Dys clinical gene therapy space (Figure 1).”
Therapy of Genetic Disorders: Novel Therapies for Duchenne Muscular Dystrophy
Seto, J. T., Bengtsson, N. E., & Chamberlain, J. S. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0044-x · Cited by 41
“Priming of the dystrophin T-cell activity was thought to have occurred through low levels of dystrophin that are produced naturally in rare, socalled ‘revertant fibers’ found in most DMD patients [45].”
BackgroundWooddell, C. I., Hegge, J., Zhang, G., Sebestyén, M. G., Noble, M., Griffin, J. B., Pfannes, L. V., Herweijer, H., Hagstrom, J. E., Braun, S., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.160 · Cited by 35
“As with most other gene therapies, an immune response to the transgene must be addressed (Mendell et al., 2010).”
BackgroundGene therapy vector-related myocarditis
Silver, E., Argirò, A., Hong, K. N., & ADLER, E. D. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131617 · Cited by 36
Comparative Genomics of X-linked Muscular Dystrophies: The Golden Retriever Model
Brinkmeyer‐Langford, C., & Kornegay, J. N. (2013) · Current Genomics · doi:10.2174/13892029113149990004 · Cited by 40
“exon skipping [65-69], stop codon read-through [13, 15, 70, 71], and other methods that introduce the DMD gene directly [72-76].”
Viral vector-mediated gene therapies
Hollinger, K., & Chamberlain, J. S. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000241 · Cited by 35
“In particular, the development of miniaturized ‘microdystrophins’ has enabled delivery of therapeutic cassettes to dystrophic muscles in animal models in early phase clinical trials using AAV vectors [4,5].”
BackgroundD’Amario, D., Gowran, A., Canonico, F., Castiglioni, E., Rovina, D., Santoro, R., Spinelli, P., Adorisio, R., Amodeo, A., Perrucci, G. L., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7090291 · Cited by 36
“5 mini-dystrophin was delivered through intramuscular injection in the bicep muscle of six DMD boys (Phase I clinical trial, NCT00428935) which lead to effective gene delivery to the muscle cells with low immunological reaction to the viral vector; nevertheless, only very few dystrophin-positive myofibres were detecte…”
BackgroundMethodSzwec, S., Kapłucha, Z., Chamberlain, J. S., & Konieczny, P. (2023) · BioDrugs · doi:10.1007/s40259-023-00632-3 · Cited by 38
“The immune response can also be activated by the newly generated dystrophin [103, 107, 112, 122, 123].”
BackgroundÄijö, T., Edelman, S., Lönnberg, T., Larjo, A., Kallionpää, H., Tuomela, S., Engström, E., Lahesmaa, R., & Lähdesmäki, H. J. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-572 · Cited by 38
“These patients develop dystrophin specific autoreactive T cells [31], however, the biological role for dystrophin or palladin in differentiating Th cells is not known.”
BackgroundHayashita‐Kinoh, H., Yugeta, N., Okada, H., Nitahara‐Kasahara, Y., Chiyo, T., Okada, T., & Takeda, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.5 · Cited by 37
Nanotherapy for Duchenne muscular dystrophy
Nance, M. E., Hakim, C. H., Yang, N. N., & Duan, D. (2017) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1472 · Cited by 37
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Tarantal, A. F., Lee, C. C. I., Martinez, M. L., Asokan, A., & Samulski, R. J. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.130 · Cited by 32
Self-citationBočkor, L., Bortolussi, G., Iaconcig, A., Chiaruttini, G., Tiribelli, C., Giacca, M., Benvenuti, F., Zentilin, L., & Muro, A. F. (2017) · Gene Therapy · doi:10.1038/gt.2017.75 · Cited by 32
Progress in gene therapy of dystrophic heart disease
Lai, Y., & Duan, D. (2012) · Gene Therapy · doi:10.1038/gt.2012.10 · Cited by 36
Masat, E., Laforêt, P., Antonio, M. D., Corre, G., Perniconi, B., Taouagh, N., Mariampillai, K., Amelin, D., Mauhin, W., Hogrel, J., et al. (2016) · Scientific Reports · doi:10.1038/srep36182 · Cited by 33
“Additionally, underlying inflammation associated with some diseases can enhance immune responses against protein and gene therapeutics 38,39 .”
Tanboon, J., Uruha, A., Arahata, Y., Dittmayer, C., Schweizer, L., Goebel, H., Nishino, I., & Stenzel, W. (2021) · Brain Pathology · doi:10.1111/bpa.12962 · Cited by 32
“(61, 62, 63) This phenomenon, often times mentioned as “accompanying inflammatory changes,” if correctly diagnosed individually may open (additional) therapeutic approaches even in primarily genetic diseases such as Duchenne muscular dystrophy (DMD) (64) or dysferlinopathy (LGMDR2) and anoctaminopathy (LGMDR12) (65),…”
BackgroundDavey, M. G., Riley, J. S., Andrews, A., Tyminski, A., Limberis, M., Pogoriler, J. E., Partridge, E., Olive, A., Hedrick, H. L., Flake, A. W., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171132 · Cited by 30
Ke, Q., Zhao, Z.-Y., Mendell, J. R., Baker, M. W., Wiley, V. C., Kwon, J. M., Alfano, L. N., Connolly, A. M., Jay, C., Polari, H., et al. (2019) · World Journal of Pediatrics · doi:10.1007/s12519-019-00242-6 · Cited by 33
Self-citationTLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
Kumar, S. R. P., Biswas, M., Cao, D., Arisa, S., Muñoz-Melero, M., Lam, A. K., Piñeros, A. R., Kapur, R., Kaisho, T., Kaufman, R. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.029 · Cited by 31
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 32
Self-citationSelot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
“AAV vectors have been successful in phase I/II studies for hemophilia B, cystic fibrosis, alpha-1 anti-trypsin deficiency, Parkinson disease, Duchenne muscular dystrophy and Leber’s congenital amaurosis [7-12].”
Gene Transfer Therapy for Neurodevelopmental Disorders
Özlü, C., Bailey, R. M., Sinnett, S. E., & Goodspeed, K. (2021) · Developmental Neuroscience · doi:10.1159/000515434 · Cited by 34
Gene Therapy for Inherited Muscle Diseases: Where Genetics Meets Rehabilitation Medicine
Braun, R. G., Wang, Z., Mack, D. L., & Childers, M. K. (2014) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000000138 · Cited by 37
“Another phase I trial on DMD from Mendell et al.(15) also raised the potential of cellular immune responses to either self or nonself dystrophin epitopes.”
BackgroundEvaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne
Lourbakos, A., Yau, N., de Bruijn, P., Hiller, M., Kozaczynska, K., Jean-Baptiste, R., Reza, M., Wolterbeek, R., Koeks, Z., Ayoglu, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17982-y · Cited by 31
Gene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 37
Carpentier, M., Lorain, S., Chappert, P., Lalfer, M., Hardet, R., Urbain, D., Peccate, C., Adriouch, S., Garcia, L., Davoust, J., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.235 · Cited by 25
Atomic structure of a rationally engineered gene delivery vector, AAV2. 5
Burg, M., Rosebrough, C., Drouin, L. M., Bennett, A., Mietzsch, M., Chipman, P., McKenna, R., Sousa, D., Potter, M., Byrne, B., et al. (2018) · Journal of Structural Biology · doi:10.1016/j.jsb.2018.05.004 · Cited by 30
Self-citationClinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 31
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
“74,75 Moreover, the context of the immune environment and signaling directs the formation of host response, as observed through the complexity of immune surveillance in more tolerogenic tissues such as the liver.”
Towards the clinical translation of optogenetic skeletal muscle stimulation
Gundelach, L. A., Hüser, M. A., Beutner, D., Ruther, P., & Bruegmann, T. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02387-0 · Cited by 30
“Furthermore, intramuscular administration of an AAV vector encoding microdystrophin to Duchenne muscular dystrophy patients also led to an immune response against the transgene [93].”
BackgroundClinical Pharmacology Considerations on Recombinant Adeno‐Associated Virus–Based Gene Therapy
Sun, K., & Liao, M. Z. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2141 · Cited by 37
Circulating Biomarkers for Duchenne Muscular Dystrophy
Aartsma-Rus, A. M., & Spitali, P. (2015) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-150102 · Cited by 32
Drug Discovery of Therapies for Duchenne Muscular Dystrophy
Blat, Y., & Blat, S. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115586535 · Cited by 34
Ouisse, L.-H., Remy, S., Lafoux, A., Larcher, T., Tesson, L., Chenouard, V., Guillonneau, C., Brusselle, L., Vimond, N., Rouger, K., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02131 · Cited by 25
“Apart from inflammation and innate immune responses, adaptive immune responses including anti-dystrophin T cells and Treg cells are also present in DMDpatients (9, 11) andmdxmice (6, 12, 13).”
BackgroundDuchenne Muscular Dystrophy: the Heart of the Matter
Shih, J. A., Folch, A., & Wong, B. L. Y. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00456-0 · Cited by 31
Genomic Safe Harbor Expression of PAX7 for the Generation of Engraftable Myogenic Progenitors
Kim, H., Selvaraj, S., Kiley, J., Azzag, K., Garay, B. I., & Perlingeiro, R. C. R. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.11.001 · Cited by 31
“Much current effort is focused on the development of adeno-associated virus (AAV)-mediated gene therapy approaches, which have advanced to the clinical trial stage for the treatment of Duchenne MD (Bowles et al., 2012; Mendell et al., 2010), among a few others (Crudele and Chamberlain, 2019).”
BackgroundStarikova, A. V., Skopenkova, V. V., Polikarpova, A. V., Reshetov, D. A., Vassilieva, S. G., Velyaev, O. A., Shmidt, A. A., Savchenko, I. M., Soldatov, V. O., Egorova, T. V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-04892-x · Cited by 32
Long, B. R., Robinson, T. M., Day, J. R., Yu, H., Lau, K., Imtiaz, U., Patton, K. S., de Hart, G., Henshaw, J., Agarwal, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.033 · Cited by 31
“33 This cytolytic targeting is suspected to result in the observations of increased ALT and, in some cases, an associated decline in transgene expression as the transduced cells are lost.”
Sitzia, C., Farini, A., Jardim, L. S., Razini, P., Belicchi, M., Cassinelli, L., Villa, C., Erratico, S., Parolini, D., Bella, P., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.163 · Cited by 29
Dupont, J.-B., Guo, J., Renaud-Gabardos, E., Poulard, K., Latournerie, V., Lawlor, M. W., Grange, R. W., Gray, J. T., Buj‐Bello, A., Childers, M. K., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.10.018 · Cited by 29
Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
“26 One patient in the low-dose (2 · 10 10 vg/kg) cohort also had pre-existing cellular responses against revertant dystrophin that seemed to accelerate the development of T cell response after gene transfer in this patient.”
MicroRNA-206 Downregulation Improves Therapeutic Gene Expression and Motor Function in mdx Mice
Bulaklak, K., Xiao, B., Qiao, C., Li, J., Patel, T., Jin, Q., Li, J., & Xiao, X. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.011 · Cited by 29
“Immune reactions to the recombinant dystrophin protein have also been reported in clinical trials.(9) This has spurred further exploration into alternative therapies that can address these shortcomings.”
BackgroundSelf-citationNeurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy
Leigh, F., Ferlini, A., Biggar, D., Bushby, K. M. D., Finkel, R. S., Morgenroth, L. P., & Wagner, K. R. (2018) · PEDIATRICS · doi:10.1542/peds.2018-0333c · Cited by 29
Heydemann, A., & Siemionow, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030830 · Cited by 34
“However, at 90 days post-injection no dystrophin DNA was detected, likely due to an immune response [48,49].”
BackgroundIshibashi, Y., Sung, C. Y. W., Grati, M., & Chien, W. W. (2023) · Hearing Research · doi:10.1016/j.heares.2023.108735 · Cited by 30
“…with Duchenne muscular dystrophy (an X-linked genetic disorder caused by mutations in the dystrophin gene which leads to progressive muscle wasting) who received AAV2-mediated gene therapy to deliver a mini-dystrophin transgene developed dystrophin-specific T cell immunity ( Mendell et al., 2010 ).”
Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy
Liew, W. K. M., & Kang, P. B. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612472386 · Cited by 30
Metadata
- Authors
- Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., Malik, V., Coley, B., Clark, K. R., Li, J., Xiao, X., Samulski, J., McPhee, S. W., Samulski, R. J., & Walker, C. M.
- Affiliations
- Nationwide Children's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- AskBio (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-07
- Volume
- 363
- Issue
- 15
- Pages
- 1429-1437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3014106
- OpenAlex
- W2116885047
- Cited by
- 655
- References
- 25
- Citations by year
- 2026: 21 · 2025: 22 · 2024: 38 · 2023: 44 · 2022: 49 · 2021: 42 · 2020: 44 · 2019: 47 · 2018: 31 · 2017: 42 · 2016: 28 · 2015: 47 · 2014: 34 · 2013: 54 · 2012: 60
- FWCI
- 21.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI060388)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- Duchenne muscular dystrophy, dystrophin, autoreactive T cells, T cell immunity, dystrophin gene deletion
- MeSH terms
- Dependovirus, Autoantibodies, Child, DNA, Viral, Genetic Vectors, Humans, Immunity, Cellular, Male, T-Lymphocytes, Protein Biosynthesis, Genetic Therapy, Autoimmunity, Dystrophin, Frameshift Mutation, Muscle, Skeletal, Transgenes, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.